gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2024-34-6-100-119gastro-j-1468Research ArticleСОГЛАШЕНИЕ СПЕЦИАЛИСТОВEXPERTS’ AGREEMENTДиагностика и лечение пациентов с аутоиммунным гепатитом (соглашение специалистов)Diagnosis and Treatment of Patients with Autoimmune Hepatitis (Experts’ Agreement)https://orcid.org/0000-0003-4291-812XСандлерЮ. Г.SandlerYu. G.

Сандлер Юлия Григорьевна — кандидат медицинских наук, старший научный сотрудник отдела гепатологии

111123, г. Москва, ш. Энтузиастов, 86

Yuliya G. Sandler — Cand. Sci. Med., Senior Researcher of the Department of Hepatology

111123, Moscow, Entuziastov highway, 86 

sandlerjulia2012@gmail.comhttps://orcid.org/0000-0002-0344-8375ВинницкаяЕ. В.VinnitskayaE. V.

Винницкая Елена Владимировна — доктор медицинских наук, заведующая отделом гепатологии

111123, г. Москва, ш. Энтузиастов, 86

Elena V. Vinnitskaya — Dr. Sci. (Med.), Head of the Department of Hepatology

111123, Moscow, Entuziastov highway, 86

evinn@mail.ruhttps://orcid.org/0000-0002-8821-6142РайхельсонК. Л.RaikhelsonK. L.

Райхельсон Карина Леонидовна — доктор медицинских наук, профессор Научно-клинического и образовательного центра гастроэнтерологии и гепатологии

199226, г. Санкт-Петербург, ул. Кораблестроителей, 20, корп. 1.

Karina L. Raikhelson — Dr. Sci. (Med.), Professor of the Scientific and Educational Center of Gastroenterology and Hepatology

199226, Saint Petersburg, Korablestroiteley str., 20–1

kraikhelson@mail.ruhttps://orcid.org/0000-0002-5699-541XИвашкинК. В.IvashkinK. V.

Ивашкин Константин Владимирович — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского

119435, г. Москва, ул. Погодинская, 1, стр. 1

Konstantin V. Ivashkin — Dr. Sci. Med., Professor of the Department of Propaedeutics of Internal Medicine, Gastroenterology and Hepatology

119435, Moscow, Pogodinskaya str., 1, build. 1

ivashkin_k_v_1@staff.sechenov.ruhttps://orcid.org/0000-0002-5917-203XБацкихС. Н.BatskikhS. N.

Бацких Сергей Николаевич — доктор медицинских наук, ведущий научный сотрудник отдела гепатологии

111123, г. Москва, ш. Энтузиастов, 86

Sergey N. Batskikh — Dr. Sci. (Med.), Leading Researcher of the Department of Hepatology

111123, Moscow, Entuziastov highway, 86

zdoc@mail.ruhttps://orcid.org/0000-0003-4074-5907АлександроваЕ. Н.AleksandrovaE. N.

Александрова Елена Николаевна — доктор медицинских наук, заведующая лабораторией клинической иммунологии

111123, г. Москва, ш. Энтузиастов, 86

Elena N. Aleksandrova — Dr. Sci. (Med.), Head of the Laboratory of Clinical Immunology

111123, Moscow, Entuziastov highway, 86

aleksandrovaen2015@yandex.ruhttps://orcid.org/0000-0002-3160-2771АбдурахмановД. Т.AbdurakhmanovD. T.

Абдурахманов Джамал Тинович — доктор медицинских наук, профессор кафедры внутренних, профессиональных болезней и пульмонологии

119435, г. Москва, ул. Погодинская, 1, стр. 1

Dzhamal T. Abdurakhmanov — Dr. Sci. (Med.), Professor of the Department of Internal, Occupational Diseases and Pulmonology

119435, Moscow, Pogodinskaya str., 1, build. 1

abdurakhmanov_d_t@staff.sechenov.ruhttps://orcid.org/0000-0001-7069-2725АбдулганиеваД. И.AbdulganievaD. I.

 Абдулганиева Диана Ильдаровна — доктор медицинских наук, профессор, заведующая кафедрой госпитальной терапии

420012, г. Казань, ул. Бутлерова, 49

Diana I. Abdulganieva — Dr. Sci. Med., Professor, Head of the Department of Hospital Therapy

420012, Kazan, Butlerova str., 49

diana_s@mail.ruhttps://orcid.org/0000-0002-6151-2021БакулинИ. Г.BakulinI. G.

Бакулин Игорь Геннадьевич — доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса

191015, г. Санкт-Петербург, ул. Кирочная, 41

Igor G. Bakulin — Dr. Sci. (Med.), Professor, Head of the Department of Propaedeutics of Internal Medicine, Gastroenterology and Dietetics named after S.M. Ryss

191015, Saint Petersburg, Kirochnaya str., 41

igbakulin@yandex.ruhttps://orcid.org/0000-0002-5041-3466БуеверовА. О.BueverovA. O.

Буеверов Алексей Олегович — доктор медицинских наук, профессор кафедры медико-социальной экспертизы, неотложной и патогенетической терапии

119435, г. Москва, ул. Погодинская, 1, стр. 1

Alexey O. Bueverov — Dr. Sci. (Med.), Professor at the Department of Medical and Social Expertise, Emergency and Pathogenetic Therapy

119435, Moscow, Pogodinskaya str., 1, build. 1

bueverov_a_o@staff.sechenov.ruhttps://orcid.org/0000-0002-7817-9069ВоробьевС. Л.VorobyevS. L.

Воробьев Сергей Леонидович — кандидат медицинских наук, директор

192071, г. Санкт-Петербург, просп. Славы, 32, лит. А

Sergey L. Vorobyev — Cand. Sci. (Med.), Director

192071, Saint Petersburg, Slavy Ave., 32, lit. A

ncmd@ncmd.ruhttps://orcid.org/0000-0003-2690-5062ГерасимоваО. А.GerasimovaO. A.

Герасимова Ольга Анатольевна — доктор медицинских наук, профессор Научно-клинического и образовательного центра гастроэнтерологии и гепатологии; руководитель амбулаторного центра трансплантологии, гепатологии и нефрологии

199226, г. Санкт-Петербург, ул. Кораблестроителей, 20, корп. 1

Olga A. Gerasimova — Dr. Sci. Med., Professor of the Scientific and Educational Center of Gastroenterology and Hepatology; Head of the Outpatient Center for Transplantology, Hepatology and Nephrology

199226, Saint Petersburg, Korablestroiteley str., 20–1

ren321@mail.ruhttps://orcid.org/0000-0003-2569-1699ДолгушинаА. И.DolgushinaA. I.

Долгушина Анастасия Ильинична — доктор медицинских наук, заведующая кафедрой госпитальной терапии

454092, г. Челябинск, ул. Воровского, 64

Anastasia I. Dolgushina — Dr. Sci. (Med.), Head of the Department of Hospital Therapy

454092, Chelyabinsk, Vorovskogo str., 64

dolgushinaai@yandex.ruhttps://orcid.org/0000-0003-4838-5707ЖуравлеваМ. С.ZhuravlevaM. S.

Журавлева Мария Сергеевна — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса

191015, г. Санкт-Петербург, ул. Кирочная, 41

Mariia S. Zhuravleva — Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutics of Internal Medicine, Gastroenterology and Dietetics named after S.M. Ryss

191015, Saint Petersburg, Kirochnaya str., 41

mariya.zhuravleva@szgmu.ruhttps://orcid.org/0000-0001-6029-1864ИльченкоЛ. Ю.IlchenkoL. Yu.

Ильченко Людмила Юрьевна — доктор медицинских наук, профессор, профессор кафедры госпитальной терапии им. академика Г.И. Сторожакова

117513, г. Москва, ул. Островитянова, 1

Liudmila Yu. Ilchenko — Dr. Sci. (Med.), Professor, Professor of the Department of Hospital Therapy named after Academician G.I. Storozhakov, N.I. Pirogov Russian National Research Medical University

117513, Moscow, Ostrovityanova str., 1

ilchenko-med@yandex.ruhttps://orcid.org/0000-0002-7972-1286КаревВ. Е.KarevV. E.

Карев Вадим Евгеньевич — доктор медицинских наук, руководитель отдела тканевых и патоморфологических методов исследования

197022, г. Санкт-Петербург, ул. Профессора Попова, 9

Vadim E. Karev — Dr. Sci. (Med.), Head of the Department of Tissue and Pathomorphological Research Methods

197022, Saint Petersburg, Professora Popova str., 9

vadimkarev@yandex.ruhttps://orcid.org/0000-0002-5538-9418КорочанскаяН. В.KorochanskayaN. V.

Корочанская Наталья Всеволодовна — доктор медицинских наук, профессор кафедры хирургии № 3 факультета повышения квалификации и профессиональной переподготовки специалистов

350063, г. Краснодар, ул. Митрофана Седина, 4

 Natalia V. Korochanskaya — Dr. Sci. (Med.), Professor of the Department of Surgery No. 3 of the Faculty of Advanced Training and Professional Retraining of Specialists

350063, Krasnodar, Mitrofana Sedina str., 4 

nvk-gastro@mail.ruhttps://orcid.org/0000-0001-9840-7885КляритскаяИ. Л.KliaritskaiaI. L.

Кляритская Ирина Львовна — доктор медицинских наук, профессор, заведующая кафедрой терапии, гастроэнтерологии, кардиологии и общей врачебной практики (семейной медицины) факультета  подготовки медицинских кадров высшей квалификации и  дополнительного профессионального образования Медицинской академии им. С.И. Георгиевского

295051, г. Симферополь, б-р Ленина, 5/7

Irina L. Kliaritskaia — Dr. Sci. (Med.), Professor, Head of the Department of Therapy, Gastroenterology, Cardiology and General Medical Practice (Family Medicine) of the Fa-culty of Training of Highly Qualified Medical Personnel and Continuing Professional Education of the S.I. Georgievsky Medical Academy

295051, Simferopol, Lenina Blvd, 5/7

klira3@yandex.ruhttps://orcid.org/0000-0003-0889-2720КарнауховН. С.KarnaukhovN. S.

Карнаухов Николай Сергеевич — кандидат медицинских наук, заведующий отделом патоморфологии

111123, г. Москва, ш. Энтузиастов, 86

Nikolay S. Karnaukhov — Cand. Sci. (Med.), Head of the Department of Pathomorphology

111123, Moscow, Entuziastov highway, 86

nick07@bk.ruhttps://orcid.org/0000-0002-4998-3699ЛапинС. В.LapinS. V.

Лапин Сергей Владимирович — кандидат медицинских наук, заведующий лабораторией диагностики аутоиммунных заболеваний Научно-методического центра по молекулярной медицине Министерства  здравоохранения Российской Федерации

197101, г. Санкт-Петербург, ул. Льва Толстого, 6-8

Sergey V. Lapin — Cand. Sci. (Med.), Head of the Laboratory for Diagnostics of Autoimmune Diseases of the Scientific and Methodological Center for Molecular Medicine of the Ministry of Health of the Russian Federation

197101, Saint Petersburg, L’va Tolstovo str., 6-8

svlapin@mail.ruhttps://orcid.org/0000-0002-6581-7017ЛивзанМ. А.LivzanM. A.

Ливзан Мария Анатольевна — доктор медицинских наук, профессор, член-корреспондент РАН, заведующий кафедрой факультетской терапии и гастроэнтерологии, ректор

644099, Россия, г. Омск, ул. Ленина, 12

Maria A. Livzan — Dr. Sci. (Med.), Corresponding Member of the Russian Academy of Sciences, Professor, Head of the Department of Faculty Therapy and Gastroenterology, Rector

644099, Omsk, Lenina str., 12

mlivzan@yandex.ruhttps://orcid.org/0000-0001-8913-140XМаевскаяМ. В.MaevskayaM. V.

Маевская Марина Викторовна — доктор медицинских наук, профессор, консультант лечебно-диагностического отделения Университетской клинической больницы № 2

119048, г. Москва, ул. Трубецкая, 8, стр. 2

Marina V. Maevskaya — Dr. Sci. (Med.), Professor, Consultant at the Diagnostic and Treatment Department of the University Clinical Hospital No. 2

119048, Moscow, Trubetskaya str., 8/2

mvmaevskaya@me.comhttps://orcid.org/0000-0002-6738-6417МарченкоН. В.MarchenkoN. V.

Марченко Наталья Валерьевна — кандидат медицинских наук, доцент Научно-клинического и образовательного центра гастроэнтерологии и гепатологии, ФГБОУ ВО «Санкт-Петербургский государственный университет»; врач-гастроэнтеролог

199226, г. Санкт-Петербург, ул. Кораблестроителей, 20, корп. 1

Natalia V. Marchenko — Cand. Sci. Med., Associate Professor of the Scientific and Educational Center of Gastroenterology and Hepatology, Saint Petersburg State University; Gastroenterologist

199226, Saint Petersburg, Korablestroiteley str., 20

dr.marchenko@gmail.comhttps://orcid.org/0000-0001-6376-9392НекрасоваТ. П.NekrasovaT. P.

Некрасова Татьяна Петровна — кандидат медицинских наук, доцент, Институт клинической морфологии и цифровой патологии

119435, г. Москва, ул. Погодинская, 1, стр. 1

Tatiyana P. Nekrasova — Cand. Sci. (Med.), Associate Professor at the Institute of Clinical Morphology and Digital Pathology

119435, Moscow, Pogodinskaya str., 1, build. 1

nekrasova_t_p@staff.sechenov.ruhttps://orcid.org/0000-0003-1699-0881НикитинИ. Г.NikitinI. G.

Никитин Игорь Геннадьевич — доктор медицинских наук, профессор, заведующий кафедрой госпитальной терапии № 2 лечебного факультета

117513, г. Москва, ул. Островитянова, 1 

Igor G. Nikitin — Dr. Sci. (Med.), Professor, Head of the Department of Hospital Therapy No. 2 of the Faculty of Therapy

117513, Moscow, Ostrovityanova str., 1

igor.nikitin.64@mail.ruhttps://orcid.org/0000-0002-2738-2956НовиковА. А.NovikovA. A.

Новиков Александр Александрович — доктор биологических наук, ведущий научный сотрудник лаборатории клинической иммунологии

111123, г. Москва, ш. Энтузиастов, 86

Alexander A. Novikov — Dr. Sci. (Med.), Leading Researcher of the Laboratory of Clinical Immunology

111123, Moscow, Entuziastov highway, 86

a.novikov@mknc.ruhttps://orcid.org/0000-0003-2839-100XСайфутдиновР. Г.SaifutdinovR. G.

Сайфутдинов Рафик Галимзянович — доктор медицинских наук, заведующий кафедрой терапии

420012, г. Казань, ул. Бутлерова, 36

Rafik G. Saifutdinov — Dr. Sci. (Med.), Head of the Department of Therapy

420012, Kazan, Butlerova str., 36 

rgsbancorp@mail.ruhttps://orcid.org/0000-0002-8563-6870СказываеваЕ. В.SkazyvaevaE. V.

Сказываева Екатерина Васильевна — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса

191015, г. Санкт-Петербург, ул. Кирочная, 41

Ekaterina V. Skazyvaeva — Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutics of Internal Medicine, Gastroenterology and Dietetics named after S.M. Ryss

191015, St. Petersburg, Kirochnaya str., 41

eskazyvaeva@yandex.ruhttps://orcid.org/0000-0001-8391-5211СюткинВ. Е.SyutkinV. E.

Сюткин Владимир Евгеньевич — доктор медицинских наук, профессор кафедры хирургии с курсами онкохирургии, эндоскопии, хирургической патологии, клинической трансплантологии и органного донорства; ведущий научный сотрудник отделения трансплантации печени

129010, г. Москва, Большая Сухаревская пл., 3

Vladimir E. Syutkin — Dr. Sci. (Med.), Professor of the Department of Surgery with Courses in Oncosurgery, Endoscopy, Surgical Pathology, Clinical Transplantology and Organ Donation; Leading Researcher of the Liver Transplant Department

129010, Moscow, Bolshaya Sukharevskaya sq., 3

vladsyutkin@gmail.comhttps://orcid.org/0000-0002-5402-8266ПрашноваМ. К.PrashnovaM. K.

Прашнова Мария Константиновна — кандидат медицинских наук, доцент Научно-клинического и образовательного центра гастроэнтерологии и гепатологии

199226, г. Санкт-Петербург, ул. Кораблестроителей, 20, корп. 1

Mariya K. Prashnova — Cand. Sci. (Med.), Teaching Assistant of the Scientific and Educational Center of Gastroenterology and Hepatology

199226, Saint Petersburg, Korablestroiteley str., 20

prashnova@mail.ruhttps://orcid.org/0000-0002-4599-4040ХайменоваТ. Ю.KhaymenovaT. Yu.

Хайменова Татьяна Юрьевна — кандидат медицинских наук, заведующая отделением заболеваний печени

111123, г. Москва, ш. Энтузиастов, 86

Tatyana Yu. Khaymenova — Cand. Sci. (Med.), Head of the Department of Liver Diseases

111123, Moscow, Entuziastov highway, 86

t.khaimenova@mknc.ruhttps://orcid.org/0000-0003-4308-8009ХомерикиС. Г.KhomerikS. G.

Хомерики Сергей Германович — доктор медицинских наук, профессор, заведующий лаборатории патоморфологии

111123, г. Москва, ш. Энтузиастов, 86

Sergey G. Khomeriki — Dr. Sci. (Med.), Professor, Head of the Pathomorphology Laboratory

111123, Moscow, Entuziastov highway, 86

s.homeriki@mknc.ruГБУЗ г. Москвы «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. МосквыРоссияLoginov Moscow Clinical Scientific CenterRussian FederationФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияSaint Petersburg State UniversityRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationФГБОУ ВО «Казанский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияKazan State Medical UniversityRussian FederationФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Министерства здравоохранения Российской ФедерацииРоссияNorth-Western State Medical University named after I.I. MechnikovRussian FederationООО «Национальный центр клинической морфологической диагностики»РоссияOOO National Center for Clinical Morphological DiagnosticsRussian FederationФГБОУ ВО «Санкт-Петербургский государственный университет»; ФГБУ «Российский научный центр радиологии и хирургических технологий им. академика А.М. Гранова» Министерства здравоохранения Российской ФедерацииРоссияSaint Petersburg State University; Russian Scientific Center for Radiology and Surgical Technologies named after Academician A.M. GranovRussian FederationФГБОУ ВО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSouth Ural State Medical UniversityRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияN.I. Pirogov Russian National Research Medical UniversityRussian FederationФГБУ «Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства»РоссияPediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological AgencyRussian FederationФГБОУ ВО «Кубанский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияKuban State Medical UniversityRussian FederationФГАОУ ВО «Крымский федеральный университет им. В.И. Вернадского»РоссияV.I. Vernadsky Crimean Federal UniversityRussian FederationФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияAcademician I.P. Pavlov First St. Petersburg State Medical UniversityRussian FederationФГБОУ ВО «Омский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияOmsk State Medical UniversityRussian FederationФГБУ «Российский научный центр радиологии и хирургических технологий им. академика А.М. Гранова» Министерства здравоохранения Российской ФедерацииРоссияRussian Scientific Center for Radiology and Surgical Technologies named after Academician A.M. GranovRussian FederationКазанская государственная медицинская академия — филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияKazan State Medical Academy — Branch Campus of the Russian Medical Academy of Continuous Professional EducationRussian FederationМедико-биологический университет инноваций и непрерывного образования, ФГБУ «Государственный научный центр Российской Федерации — Федеральный медицинский биофизический центр им. А.И. Бурназяна»; ГБУЗ г. Москвы «НИИ скорой помощи им. Н.В. Склифосовского» Департамента здравоохранения г. МосквыРоссияMedical and Biological University of Innovation and Continuous Education, State Research Center — Byrnasyan Federal Medical Biophysical Center of Federal Biological Agency; N.V. Sklifosovsky Research Institute for Emergency Care of the Moscow City Health DepartmentRussian Federation202430122024346100119Copyright © Сандлер Ю.Г., Винницкая Е.В., Райхельсон К.Л., Ивашкин К.В., Бацких С.Н., Александрова Е.Н., Абдурахманов Д.Т., Абдулганиева Д.И., Бакулин И.Г., Буеверов А.О., Воробьев С.Л., Герасимова О.А., Долгушина А.И., Журавлева М.С., Ильченко Л.Ю., Карев В.Е., Корочанская Н.В., Кляритская И.Л., Карнаухов Н.С., Лапин С.В., Ливзан М.А., Маевская М.В., Марченко Н.В., Некрасова Т.П., Никитин И.Г., Новиков А.А., Сайфутдинов Р.Г., Сказываева Е.В., Сюткин В.Е., Прашнова М.К., Хайменова Т.Ю., Хомерики С.Г., 20252025Сандлер Ю.Г., Винницкая Е.В., Райхельсон К.Л., Ивашкин К.В., Бацких С.Н., Александрова Е.Н., Абдурахманов Д.Т., Абдулганиева Д.И., Бакулин И.Г., Буеверов А.О., Воробьев С.Л., Герасимова О.А., Долгушина А.И., Журавлева М.С., Ильченко Л.Ю., Карев В.Е., Корочанская Н.В., Кляритская И.Л., Карнаухов Н.С., Лапин С.В., Ливзан М.А., Маевская М.В., Марченко Н.В., Некрасова Т.П., Никитин И.Г., Новиков А.А., Сайфутдинов Р.Г., Сказываева Е.В., Сюткин В.Е., Прашнова М.К., Хайменова Т.Ю., Хомерики С.Г.Sandler Y.G., Vinnitskaya E.V., Raikhelson K.L., Ivashkin K.V., Batskikh S.N., Aleksandrova E.N., Abdurakhmanov D.T., Abdulganieva D.I., Bakulin I.G., Bueverov A.O., Vorobyev S.L., Gerasimova O.A., Dolgushina A.I., Zhuravleva M.S., Ilchenko L.Y., Karev V.E., Korochanskaya N.V., Kliaritskaia I.L., Karnaukhov N.S., Lapin S.V., Livzan M.A., Maevskaya M.V., Marchenko N.V., Nekrasova T.P., Nikitin I.G., Novikov A.A., Saifutdinov R.G., Skazyvaeva E.V., Syutkin V.E., Prashnova M.K., Khaymenova T.Y., Khomerik S.G.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1468

Введение. В последнее десятилетие существенно углубилось понимание патогенеза аутоиммунного гепатита (АИГ), пересмотрены некоторые вопросы диагностики, на основании результатов новых клинических исследований оптимизированы схемы иммуносупрессивной терапии.Материалы и методы. Последние Российские клинические рекомендации по диагностике и лечению АИГ были представлены в 2013 г. В 2017 г. было создано первое Российское соглашение по вопросам диагностики и лечения АИГ. Обновление подходов к ведению пациентов с АИГ обусловило необходимость очередной систематизации для применения в клинической практике. В феврале 2024 г. состоялась заключительная сессия по обсуждению положений второго соглашения по диагностике и лечению АИГ.Результаты. В настоящей публикации представлены основные положения соглашения, касающиеся методов и алгоритмов выявления аутоантител, роли биопсии печени, пересмотренных морфологических критериев АИГ, оптимизированных схем иммуносупрессивной терапии, а также обновленных критериев оценки ответа на терапию.Выводы. Соглашение стало итогом работы группы российских экспертов по диагностике и лечению АИГ и представляет собой основу для создания обновленных федеральных клинических рекомендаций.

Background. In the last decade, the understanding of the pathogenesis of autoimmune hepatitis (AIH) has significantly deepened, based on the results of new clinical studies some diagnostic issues have been revised and immunosuppressive therapy regimens have been optimized.Materials and methods. The latest Russian clinical guidelines for the diagnosis and treatment of AIH were presented in 2013; and in 2017, the first Russian agreement on the diagnosis and treatment of AIH was held. Updating approaches to the management of patients with AIH necessitated next systematization for use in clinical practice. In February 2024, the final session was held to discuss the provisions of the second agreement on the diagnosis and treatment of AIH.Results. This publication presents the main discussion points of the agreement regarding methods and algorithms for detecting autoantibodies, the role of liver biopsy, revised morphological criteria for AIH, optimized immunosuppressive therapy regimens, updated criteria for assessing the response to therapy.Conclusions. The agreement was the result of the work of a group of experts on the diagnosis and treatment of AIH and represents the basis for the creation of updated federal clinical guidelines.

аутоиммунный гепатитсоглашениеаутоантителаиммуносупрессивная терапияфедеральные клинические рекомендацииautoimmune hepatitisagreementautoantibodiesimmunosuppressive therapyfederal clinical guidelinesReferencesИвашкин В.Т., Буеверов А.О., Абдулганиева Д.И. Клинические рекомендации по диагностике и лечению аутоиммунного гепатита. М., 2013.Ivashkin V.T., Bueverov A.O., Abdulganieva D.I. Clinical guidelines for the diagnosis and treatment of autoimmune hepatitis. Moscow, 2013. (In Russ.).Lamba M., Ngu J.H., Stedman C.A.M. Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2021;19(3):573–9.e1. DOI: 10.1016/j.cgh.2020.05.061Lamba M., Ngu J.H., Stedman C.A.M. Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2021;19(3):573–9.e1. DOI: 10.1016/j.cgh.2020.05.061Hahn J.W., Yang H.R., Moon J.S., Chang J.Y., Lee K., Kim G.A., et al. Global incidence and prevalence of autoimmune hepatitis, 1970-2022: A systematic review and meta-analysis. Eclinicalmedicine. 2023;65:102280. DOI: 10.1016/j.eclinm.2023.102280Hahn J.W., Yang H.R., Moon J.S., Chang J.Y., Lee K., Kim G.A., et al. Global incidence and prevalence of autoimmune hepatitis, 1970-2022: A systematic review and meta-analysis. Eclinicalmedicine. 2023;65:102280. DOI: 10.1016/j.eclinm.2023.102280van den Brand F.F., van der Veen K.S., de Boer Y.S., van Gerven N.M., Lissenberg-Witte B.I., Beuers U., et al.; Dutch Autoimmune Hepatitis Study Group. Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis. Clin Gastroenterol Hepatol. 2019;17(5):940–7.e2. DOI: 10.1016/j.cgh.2018.09.046van den Brand F.F., van der Veen K.S., de Boer Y.S., van Gerven N.M., Lissenberg-Witte B.I., Beuers U., et al.; Dutch Autoimmune Hepatitis Study Group. Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis. Clin Gastroenterol Hepatol. 2019;17(5):940–7.e2. DOI: 10.1016/j.cgh.2018.09.046Bittermann T., Lewis J.D., Levy C., Goldberg D.S. Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis. Hepatology. 2023;77(2):367–78. DOI: 10.1002/hep.32653Bittermann T., Lewis J.D., Levy C., Goldberg D.S. Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis. Hepatology. 2023;77(2):367–78. DOI: 10.1002/hep.32653Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., FalckYtter Y., Alonso-Coello P., et al.; GRADE Working Group. GRADE: An emerging consensus on rating quality 36 of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6. DOI: 10.1136/bmj.39489.470347.ADGuyatt G.H., Oxman A.D., Vist G.E., Kunz R., FalckYtter Y., Alonso-Coello P., et al.; GRADE Working Group. GRADE: An emerging consensus on rating quality 36 of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6. DOI: 10.1136/bmj.39489.470347.ADMcGonagle D., McDermott M.F. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. DOI: 10.1371/journal.pmed.0030297McGonagle D., McDermott M.F. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. DOI: 10.1371/journal.pmed.0030297Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–38. DOI: 10.1016/s0168-8278(99)80297-9Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–38. DOI: 10.1016/s0168-8278(99)80297-9Hennes E.M., Zeniya M., Czaja A.J., Parés A., Dalekos G.N., Krawitt E.L., et al.; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–76. DOI: 10.1002/hep.22322Hennes E.M., Zeniya M., Czaja A.J., Parés A., Dalekos G.N., Krawitt E.L., et al.; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–76. DOI: 10.1002/hep.22322Wang Q., Yang F., Miao Q., Krawitt E.L., Gershwin M.E., Ma X. The clinical phenotypes of autoimmune hepatitis: A comprehensive review. J Autoimmun. 2016;66:98–107. DOI: 10.1016/j.jaut.2015.10.006Wang Q., Yang F., Miao Q., Krawitt E.L., Gershwin M.E., Ma X. The clinical phenotypes of autoimmune hepatitis: A comprehensive review. J Autoimmun. 2016;66:98–107. DOI: 10.1016/j.jaut.2015.10.006Czaja A.J., Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol. 2009;15(19):2314–28. DOI: 10.3748/wjg.15.2314Czaja A.J., Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol. 2009;15(19):2314–28. DOI: 10.3748/wjg.15.2314Terziroli Beretta-Piccoli B., Mieli-Vergani G., Vergani D. Autoimmune hepatitis: Serum autoantibodies in clinical practice. Clin Rev Allergy Immunol. 2022;63(2):124–37. DOI: 10.1007/s12016-021-08888-9Terziroli Beretta-Piccoli B., Mieli-Vergani G., Vergani D. Autoimmune hepatitis: Serum autoantibodies in clinical practice. Clin Rev Allergy Immunol. 2022;63(2):124–37. DOI: 10.1007/s12016-021-08888-9Czaja A.J. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55(8):2144–61. DOI: 10.1007/s10620-010-1268-4Czaja A.J. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55(8):2144–61. DOI: 10.1007/s10620-010-1268-4Baeres M., Herkel J., Czaja A.J., Wies I., Kanzler S., Cancado E.L., et al. Establishment of standardised SLA/LP immunoassays: Specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51(2):259–64. DOI: 10.1136/gut.51.2.259Baeres M., Herkel J., Czaja A.J., Wies I., Kanzler S., Cancado E.L., et al. Establishment of standardised SLA/LP immunoassays: Specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51(2):259–64. DOI: 10.1136/gut.51.2.259Efe C., Ozaslan E., Wahlin S., Purnak T., Muratori L., Quarneti C., et al. Antibodies to soluble liver antigen in patients with various liver diseases: A multicentre study. Liver Int. 2013;33(2):190–6. DOI: 10.1111/liv.12022Efe C., Ozaslan E., Wahlin S., Purnak T., Muratori L., Quarneti C., et al. Antibodies to soluble liver antigen in patients with various liver diseases: A multicentre study. Liver Int. 2013;33(2):190–6. DOI: 10.1111/liv.12022Vergani D., Alvarez F., Bianchi F.B., Cançado E.L., Mackay I.R., Manns M.P., et al.; International Autoimmune Hepatitis Group. Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004;41(4):677–83. DOI: 10.1016/j.jhep.2004.08.002Vergani D., Alvarez F., Bianchi F.B., Cançado E.L., Mackay I.R., Manns M.P., et al.; International Autoimmune Hepatitis Group. Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004;41(4):677–83. DOI: 10.1016/j.jhep.2004.08.002Sebode M., Weiler-Normann C., Liwinski T., Schramm C. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol. 2018;9:609. DOI: 10.3389/fimmu.2018.00609Sebode M., Weiler-Normann C., Liwinski T., Schramm C. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol. 2018;9:609. DOI: 10.3389/fimmu.2018.00609Terjung B., Söhne J., Lechtenberg B., Gottwein J., Muennich M., Herzog V., et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut. 2010;59(6):808–16. DOI: 10.1136/gut.2008.157818Terjung B., Söhne J., Lechtenberg B., Gottwein J., Muennich M., Herzog V., et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut. 2010;59(6):808–16. DOI: 10.1136/gut.2008.157818Yimam K.K., Bowlus C.L. Diagnosis and classification of primary sclerosing cholangitis. Autoimmun Rev. 2014;13(4–5):445–50. DOI: 10.1016/j.autrev.2014.01.040Yimam K.K., Bowlus C.L. Diagnosis and classification of primary sclerosing cholangitis. Autoimmun Rev. 2014;13(4–5):445–50. DOI: 10.1016/j.autrev.2014.01.040Terziroli Beretta-Piccoli B., Mieli-Vergani G., Vergani D. Serology in autoimmune hepatitis: A clinical-practice approach. Eur J Intern Med. 2018;48:35–43. DOI: 10.1016/j.ejim.2017.10.006Terziroli Beretta-Piccoli B., Mieli-Vergani G., Vergani D. Serology in autoimmune hepatitis: A clinical-practice approach. Eur J Intern Med. 2018;48:35–43. DOI: 10.1016/j.ejim.2017.10.006Mack C.L., Adams D., Assis D.N., Kerkar N., Manns M.P., Mayo M.J., et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671–722. DOI: 10.1002/hep.31065Mack C.L., Adams D., Assis D.N., Kerkar N., Manns M.P., Mayo M.J., et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671–722. DOI: 10.1002/hep.31065Zachou K., Muratori P., Koukoulis G.K., Granito A., Gatselis N., Fabbri A., et al. Review article: Autoimmune hepatitis —current management and challenges. Aliment Pharmacol Ther. 2013;38:887–913.Zachou K., Muratori P., Koukoulis G.K., Granito A., Gatselis N., Fabbri A., et al. Review article: Autoimmune hepatitis —current management and challenges. Aliment Pharmacol Ther. 2013;38:887–913.European Association for the Study of the Liver. EASL clinical practice guidelines: Autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004. DOI: 10.1016/j.jhep.2015.06.030European Association for the Study of the Liver. EASL clinical practice guidelines: Autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004. DOI: 10.1016/j.jhep.2015.06.030Czaja A.J. Autoantibody-negative autoimmune hepatitis. Dig Dis Sci. 2012;57(3):610–24. DOI: 10.1007/s10620-011-2017-zCzaja A.J. Autoantibody-negative autoimmune hepatitis. Dig Dis Sci. 2012;57(3):610–24. DOI: 10.1007/s10620-011-2017-zБуеверов А.О. Серонегативный аутоиммунный гепатит. Росcийский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(2):27–33Bueverov A.O. Seronegative autoimmune hepatitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):27–33. (In Russ.).Galaski J., Weiler-Normann C., Schakat M., Zachou K., Muratori P., Lampalzer S., et al. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. J Hepatol. 2021;74(2):312–20. DOI: 10.1016/j.jhep.2020.07.032Galaski J., Weiler-Normann C., Schakat M., Zachou K., Muratori P., Lampalzer S., et al. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. J Hepatol. 2021;74(2):312–20. DOI: 10.1016/j.jhep.2020.07.032Chan E.K.L., von Mühlen C.A., Fritzler M.J., Damoiseaux J., Infantino M., Klotz W., et al.; ICAP Committee. The International Consensus on ANA Patterns (ICAP) in 2021 — The 6th Workshop and current perspectives. J Appl Lab Med. 2022;7(1):322–30. DOI: 10.1093/jalm/jfab140Chan E.K.L., von Mühlen C.A., Fritzler M.J., Damoiseaux J., Infantino M., Klotz W., et al.; ICAP Committee. The International Consensus on ANA Patterns (ICAP) in 2021 — The 6th Workshop and current perspectives. J Appl Lab Med. 2022;7(1):322–30. DOI: 10.1093/jalm/jfab140Muñoz-Sánchez G., Pérez-Isidro A., Ortiz de Landazuri I., López-Gómez A., Bravo-Gallego L.Y., Garcia-Ormaechea M., et al. on behalf of the Geai-Sei Workshop participants. Working algorithms and detection methods of autoantibodies in autoimmune liver disease: A nationwide study. Diagnostics (Basel). 2022;12(3):697. DOI: 10.3390/diagnostics12030697Muñoz-Sánchez G., Pérez-Isidro A., Ortiz de Landazuri I., López-Gómez A., Bravo-Gallego L.Y., Garcia-Ormaechea M., et al. on behalf of the Geai-Sei Workshop participants. Working algorithms and detection methods of autoantibodies in autoimmune liver disease: A nationwide study. Diagnostics (Basel). 2022;12(3):697. DOI: 10.3390/diagnostics12030697Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: Current diagnostic and clinical challenges. World J. Gastroenterol. 2008;14(21):3374–87. DOI: 10.3748/wjg.14.3374Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: Current diagnostic and clinical challenges. World J. Gastroenterol. 2008;14(21):3374–87. DOI: 10.3748/wjg.14.3374Александрова Е.Н., Дорофеев А.С., Новиков А.А., Сандлер Ю.Г. Аутоантитела при аутоиммунных заболеваниях печени (обзор литературы). Клиническая лабораторная диагностика. 2023;68(8):464–74. DOI: 10.51620/0869-2084-2023-68-8-464-474Aleksandrova E.N., Dorofeev A.S., Novikov A.A., Sandler Yu.G. Autoantibodies in autoimmune liver diseases (literature review). Russian Clinical Laboratory Diagnostics. 2023;68(8):464–74. (In Russ.). DOI: 10.51620/0869-2084-2023-68-8-464-474Laschtowitz A., Zachou K., Lygoura V., Pape S., Derben F., Jaeckel E., et al. Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. JHEP Rep. 2021;3(4):100321. DOI: 10.1016/j.jhepr.2021.100321Laschtowitz A., Zachou K., Lygoura V., Pape S., Derben F., Jaeckel E., et al. Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. JHEP Rep. 2021;3(4):100321. DOI: 10.1016/j.jhepr.2021.100321van Gerven N.M., Verwer B.J., Witte B.I., van Hoek B., Coenraad M.J., van Erpecum K.J., et al.; Dutch Autoimmune Hepatitis Working Group. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58(1):141–7. DOI: 10.1016/j.jhep.2012.09.009van Gerven N.M., Verwer B.J., Witte B.I., van Hoek B., Coenraad M.J., van Erpecum K.J., et al.; Dutch Autoimmune Hepatitis Working Group. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58(1):141–7. DOI: 10.1016/j.jhep.2012.09.009Lohse A.W., Sebode M., Bhathal P.S., Clouston A.D., Dienes H.P., Jain D., et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology. Liver Int. 2022;42(5):1058–69. DOI: 10.1111/liv.15217Lohse A.W., Sebode M., Bhathal P.S., Clouston A.D., Dienes H.P., Jain D., et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology. Liver Int. 2022;42(5):1058–69. DOI: 10.1111/liv.15217Dhaliwal H.K., Hoeroldt B.S., Dube A.K., McFarlane E., Underwood J.C., Karajeh M.A., et al. Longterm prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol. 2015;110(7):993–9. DOI: 10.1038/ajg.2015.139Dhaliwal H.K., Hoeroldt B.S., Dube A.K., McFarlane E., Underwood J.C., Karajeh M.A., et al. Longterm prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol. 2015;110(7):993–9. DOI: 10.1038/ajg.2015.139Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431–5. DOI: 10.1002/hep.1840010511Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431–5. DOI: 10.1002/hep.1840010511Hartl J., Denzer U., Ehlken H., Zenouzi R., Peiseler M., Sebode M., et al. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. J Hepatol. 2016;65(4):769–75. DOI: 10.1016/j.jhep.2016.05.023Hartl J., Denzer U., Ehlken H., Zenouzi R., Peiseler M., Sebode M., et al. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. J Hepatol. 2016;65(4):769–75. DOI: 10.1016/j.jhep.2016.05.023Lai J.C., Liang L.Y., Wong G.L. Noninvasive tests for liver fibrosis in 2024: Are there different scales for different diseases? Gastroenterol Rep (Oxf). 2024;12:goae096. DOI: 10.1093/gastro/goae096Lai J.C., Liang L.Y., Wong G.L. Noninvasive tests for liver fibrosis in 2024: Are there different scales for different diseases? Gastroenterol Rep (Oxf). 2024;12:goae096. DOI: 10.1093/gastro/goae096Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–9. DOI: 10.1016/0168-8278(95)80226-6Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–9. DOI: 10.1016/0168-8278(95)80226-6Ahn S., Jeong S.H., Cho E.J., Lee K., Kim G., Kim H. Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity. Clin Mol Hepatol. 2024;30(1):37–48. DOI: 10.3350/cmh.2023.0325Ahn S., Jeong S.H., Cho E.J., Lee K., Kim G., Kim H. Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity. Clin Mol Hepatol. 2024;30(1):37–48. DOI: 10.3350/cmh.2023.0325van Buuren H.R., Lammers W.J., Harms M.H., Hansen B.E. Surrogate endpoints for optimal therapeutic response to UDCA in primary biliary cholangitis. Dig Dis. 2015;33 Suppl 2:118–24. DOI: 10.1159/000440759van Buuren H.R., Lammers W.J., Harms M.H., Hansen B.E. Surrogate endpoints for optimal therapeutic response to UDCA in primary biliary cholangitis. Dig Dis. 2015;33 Suppl 2:118–24. DOI: 10.1159/000440759Ponsioen C.Y., Lindor K.D., Mehta R., Dimick-Santos L. Design and endpoints for clinical trials in primary sclerosing cholangitis. Hepatology. 2018;68(3):1174–88. DOI: 10.1002/hep.29882Ponsioen C.Y., Lindor K.D., Mehta R., Dimick-Santos L. Design and endpoints for clinical trials in primary sclerosing cholangitis. Hepatology. 2018;68(3):1174–88. DOI: 10.1002/hep.29882Cook G.C., Mulligan R., Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40(158):159–85. DOI: 10.1093/oxfordjournals.qjmed.a067264Cook G.C., Mulligan R., Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40(158):159–85. DOI: 10.1093/oxfordjournals.qjmed.a067264Manns M.P., Woynarowski M., Kreisel W., Lurie Y., Rust C., Zuckerman E., et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139(4):1198–206. DOI: 10.1053/j.gastro.2010.06.046Manns M.P., Woynarowski M., Kreisel W., Lurie Y., Rust C., Zuckerman E., et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139(4):1198–206. DOI: 10.1053/j.gastro.2010.06.046Pape S., Snijders R.J.A.L.M., Gevers T.J.G., Chazouilleres O., Dalekos G.N., Hirschfield G.M., et al.; International Autoimmune Hepatitis Group (IAIHG) collaborators. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol. 2022;76(4):841–9. DOI: 10.1016/j.jhep.2021.12.041Pape S., Snijders R.J.A.L.M., Gevers T.J.G., Chazouilleres O., Dalekos G.N., Hirschfield G.M., et al.; International Autoimmune Hepatitis Group (IAIHG) collaborators. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol. 2022;76(4):841–9. DOI: 10.1016/j.jhep.2021.12.041Czaja A.J. Diagnosis and management of autoimmune hepatitis: Current status and future directions. Gut Liver. 2016;10(2):177–203. DOI: 10.5009/gnl15352Czaja A.J. Diagnosis and management of autoimmune hepatitis: Current status and future directions. Gut Liver. 2016;10(2):177–203. DOI: 10.5009/gnl15352Urzúa Á., Pizarro C., Gajardo A., Poniachik R., Pavez C., Cattaneo M., et al. Autoimmune hepatitis with acute presentation: Clinical, biochemical, and histological features of 126 patients. Can J Gastroenterol Hepatol. 2022;2022:6470847. DOI: 10.1155/2022/6470847Urzúa Á., Pizarro C., Gajardo A., Poniachik R., Pavez C., Cattaneo M., et al. Autoimmune hepatitis with acute presentation: Clinical, biochemical, and histological features of 126 patients. Can J Gastroenterol Hepatol. 2022;2022:6470847. DOI: 10.1155/2022/6470847Yasui S., Fujiwara K., Yonemitsu Y., Oda S., Nakano M., Yokosuka O. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46(3):378–90. DOI: 10.1007/s00535-010-0316-3Yasui S., Fujiwara K., Yonemitsu Y., Oda S., Nakano M., Yokosuka O. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46(3):378–90. DOI: 10.1007/s00535-010-0316-3Biewenga M., Verhelst X., Baven-Pronk M., Putter H., van den Berg A., Colle I., et al.; Dutch Autoimmune Hepatitis Study Group. Aminotransferases during treatment predict long-term survival in patients with autoimmune hepatitis type 1: A landmark analysis. Clin Gastroenterol Hepatol. 2022;20(8):1776–83.e4. DOI: 10.1016/j.cgh.2021.05.024Biewenga M., Verhelst X., Baven-Pronk M., Putter H., van den Berg A., Colle I., et al.; Dutch Autoimmune Hepatitis Study Group. Aminotransferases during treatment predict long-term survival in patients with autoimmune hepatitis type 1: A landmark analysis. Clin Gastroenterol Hepatol. 2022;20(8):1776–83.e4. DOI: 10.1016/j.cgh.2021.05.024Plagiannakos C.G., Hirschfield G.M., Lytvyak E., Roberts S.B., Ismail M., Gulamhusein A.F., et al.; Canadian Network for Autoimmune Liver Disease (CaNAL). Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study. J Hepatol. 2024;81(2):227–37. DOI: 10.1016/j.jhep.2024.03.021Plagiannakos C.G., Hirschfield G.M., Lytvyak E., Roberts S.B., Ismail M., Gulamhusein A.F., et al.; Canadian Network for Autoimmune Liver Disease (CaNAL). Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study. J Hepatol. 2024;81(2):227–37. DOI: 10.1016/j.jhep.2024.03.021Grossar L., Raevens S., Van Steenkiste C., Colle I., De Vloo C., Orlent H., et al. External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort. JHEP Reports. 2024;6(9):101149. DOI: 10.1016/j.jhepr.2024.101149Grossar L., Raevens S., Van Steenkiste C., Colle I., De Vloo C., Orlent H., et al. External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort. JHEP Reports. 2024;6(9):101149. DOI: 10.1016/j.jhepr.2024.101149Czaja A.J. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29(6):816–23. DOI: 10.1111/j.1478-3231.2008.01904.xCzaja A.J. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29(6):816–23. DOI: 10.1111/j.1478-3231.2008.01904.xWang G., Tanaka A., Zhao H., Jia J., Ma X., Harada K., et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: The diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 2021;15(2):223–57. DOI: 10.1007/s12072-021-10170-1Wang G., Tanaka A., Zhao H., Jia J., Ma X., Harada K., et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: The diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 2021;15(2):223–57. DOI: 10.1007/s12072-021-10170-1Czaja A.J. Treatment of autoimmune hepatitis. Semin Liver Dis. 2002;22(4):365–78. DOI: 10.1055/s-2002-35706Czaja A.J. Treatment of autoimmune hepatitis. Semin Liver Dis. 2002;22(4):365–78. DOI: 10.1055/s-2002-35706Lamers M.M., van Oijen M.G., Pronk M., Drenth J.P. Treatment options for autoimmune hepatitis: A systematic review of randomized controlled trials. J Hepatol. 2010;53(1):191–8. DOI: 10.1016/j.jhep.2010.01.037Lamers M.M., van Oijen M.G., Pronk M., Drenth J.P. Treatment options for autoimmune hepatitis: A systematic review of randomized controlled trials. J Hepatol. 2010;53(1):191–8. DOI: 10.1016/j.jhep.2010.01.037Pape S., Gevers T.J.G., Vrolijk J.M., van Hoek B., Bouma G., van Nieuwkerk C.M.J., et al. High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. Liver Int. 2020;40(9):2164–71. DOI: 10.1111/liv.14513Pape S., Gevers T.J.G., Vrolijk J.M., van Hoek B., Bouma G., van Nieuwkerk C.M.J., et al. High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. Liver Int. 2020;40(9):2164–71. DOI: 10.1111/liv.14513Zhang C., Wu S.S., Dong X.Q., Wu Z., Zhao H., Wang G.Q. The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(52):e18313. DOI: 10.1097/MD.0000000000018313Zhang C., Wu S.S., Dong X.Q., Wu Z., Zhao H., Wang G.Q. The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(52):e18313. DOI: 10.1097/MD.0000000000018313Stellon A.J., Hegarty J.E., Portmann B., Williams R. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet. 1985;1(8430):668–70. DOI: 10.1016/s0140-6736(85)91329-7Stellon A.J., Hegarty J.E., Portmann B., Williams R. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet. 1985;1(8430):668–70. DOI: 10.1016/s0140-6736(85)91329-7Czaja A.J. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51(1):161–7. DOI: 10.1016/j.jhep.2009.02.026Czaja A.J. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51(1):161–7. DOI: 10.1016/j.jhep.2009.02.026Santiago P., Schwartz I., Tamariz L., Levy C. Systematic review with meta-analysis: Mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther. 2019;49(7):830–9. DOI: 10.1111/apt.15157Santiago P., Schwartz I., Tamariz L., Levy C. Systematic review with meta-analysis: Mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther. 2019;49(7):830–9. DOI: 10.1111/apt.15157Dalekos G.N., Arvaniti P., Gatselis N.K., Gabeta S., Samakidou A., Giannoulis G., et al. Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis. JHEP Rep. 2022;4(12):100601. DOI: 10.1016/j.jhepr.2022.100601Dalekos G.N., Arvaniti P., Gatselis N.K., Gabeta S., Samakidou A., Giannoulis G., et al. Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis. JHEP Rep. 2022;4(12):100601. DOI: 10.1016/j.jhepr.2022.100601Dalekos G.N., Arvaniti P., Gatselis N.K., Samakidou A., Gabeta S., Rigopoulou E., et al. First results from a propensity matching trial of mycophenolate mofetil vs. azathioprine in treatment-naive AIH patients. Front Immunol. 2022;12:798602. DOI: 10.3389/fimmu.2021.798602Dalekos G.N., Arvaniti P., Gatselis N.K., Samakidou A., Gabeta S., Rigopoulou E., et al. First results from a propensity matching trial of mycophenolate mofetil vs. azathioprine in treatment-naive AIH patients. Front Immunol. 2022;12:798602. DOI: 10.3389/fimmu.2021.798602Snijders R.J.A.L.M., Stoelinga A.E.C., Gevers T.J.G., Pape S., Biewenga M., Tushuizen M.E., et al.; Dutch Autoimmune Hepatitis Working Group. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis. J Hepatol. 2024;80(4):576–85. DOI: 10.1016/j.jhep.2023.11.032Snijders R.J.A.L.M., Stoelinga A.E.C., Gevers T.J.G., Pape S., Biewenga M., Tushuizen M.E., et al.; Dutch Autoimmune Hepatitis Working Group. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis. J Hepatol. 2024;80(4):576–85. DOI: 10.1016/j.jhep.2023.11.032Terziroli Beretta-Piccoli B., Mieli-Vergani G., Vergani D. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World J Gastroenterol. 2017;23(33):6030–48. DOI: 10.3748/wjg.v23.i33.6030Terziroli Beretta-Piccoli B., Mieli-Vergani G., Vergani D. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World J Gastroenterol. 2017;23(33):6030–48. DOI: 10.3748/wjg.v23.i33.6030Czaja A.J., Lindor K.D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000;119(5):1312–6. DOI: 10.1053/gast.2000.0010000001Czaja A.J., Lindor K.D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000;119(5):1312–6. DOI: 10.1053/gast.2000.0010000001Woynarowski M., Nemeth A., Baruch Y., Koletzko S., Melter M., Rodeck B., et al.; European Autoimmune Hepatitis-Budesonide Study Group. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr. 2013;163(5):1347–53.e1. DOI: 10.1016/j.jpeds.2013.05.042Woynarowski M., Nemeth A., Baruch Y., Koletzko S., Melter M., Rodeck B., et al.; European Autoimmune Hepatitis-Budesonide Study Group. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr. 2013;163(5):1347–53.e1. DOI: 10.1016/j.jpeds.2013.05.042Peiseler M., Liebscher T., Sebode M., Zenouzi R., Hartl J., Ehlken H., et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16(2):260–7.e1. DOI: 10.1016/j.cgh.2016.12.040Peiseler M., Liebscher T., Sebode M., Zenouzi R., Hartl J., Ehlken H., et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16(2):260–7.e1. DOI: 10.1016/j.cgh.2016.12.040Wiegand J., Schüler A., Kanzler S., Lohse A., Beuers U., Kreisel W., et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005;25(5):927–34. DOI: 10.1111/j.1478-3231.2005.01122.xWiegand J., Schüler A., Kanzler S., Lohse A., Beuers U., Kreisel W., et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005;25(5):927–34. DOI: 10.1111/j.1478-3231.2005.01122.xLu F.B., Hu E.D., Xu L.M., Hu Y.B., Chen L., Wu J.L., et al. Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta-analysis. Exp Ther Med. 2018;15(6):4838–50. DOI: 10.3892/etm.2018.6063Lu F.B., Hu E.D., Xu L.M., Hu Y.B., Chen L., Wu J.L., et al. Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta-analysis. Exp Ther Med. 2018;15(6):4838–50. DOI: 10.3892/etm.2018.6063Hanouneh M., Ritchie M.M., Ascha M., Ascha M.S., Chedid A., Sanguankeo A., et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. Scand J Gastroenterol. 2019;54(1):76–80. DOI: 10.1080/00365521.2018.1551498Hanouneh M., Ritchie M.M., Ascha M., Ascha M.S., Chedid A., Sanguankeo A., et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. Scand J Gastroenterol. 2019;54(1):76–80. DOI: 10.1080/00365521.2018.1551498Stoelinga A.E.C., Tushuizen M.E., van den Hout W.B., Girondo M.D.M.R., de Vries E.S., Levens A.D., et al.; Dutch Autoimmune Hepatitis Group. Tacrolimus versus mycophenolate for autoimmune hepatitis patients with incomplete response on first-line therapy (TAILOR study): A study protocol for a phase III, open-label, multicentre, randomised controlled trial. Trials. 2024;25(1):61. DOI: 10.1186/s13063-023-07832-wStoelinga A.E.C., Tushuizen M.E., van den Hout W.B., Girondo M.D.M.R., de Vries E.S., Levens A.D., et al.; Dutch Autoimmune Hepatitis Group. Tacrolimus versus mycophenolate for autoimmune hepatitis patients with incomplete response on first-line therapy (TAILOR study): A study protocol for a phase III, open-label, multicentre, randomised controlled trial. Trials. 2024;25(1):61. DOI: 10.1186/s13063-023-07832-wDe Lemos-Bonotto M., Valle-Tovo C., Costabeber A.M., Mattos A.A., Azeredo-da-Silva A.L.F. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment. Eur J Gastroenterol Hepatol. 2018;30(2):212–6. DOI: 10.1097/MEG.0000000000001019De Lemos-Bonotto M., Valle-Tovo C., Costabeber A.M., Mattos A.A., Azeredo-da-Silva A.L.F. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment. Eur J Gastroenterol Hepatol. 2018;30(2):212–6. DOI: 10.1097/MEG.0000000000001019Tannous M.M., Cheng J., Muniyappa K., Farooq I., Bharara A., Kappus M., et al. Use of tacrolimus in the treatment of autoimmune hepatitis: A single centre experience. Aliment Pharmacol Ther. 2011;34(3):405–7. DOI: 10.1111/j.1365-2036.2011.04749.xTannous M.M., Cheng J., Muniyappa K., Farooq I., Bharara A., Kappus M., et al. Use of tacrolimus in the treatment of autoimmune hepatitis: A single centre experience. Aliment Pharmacol Ther. 2011;34(3):405–7. DOI: 10.1111/j.1365-2036.2011.04749.xBaven-Pronk M.A., Hew J.M. Jr., Biewenga M., Tushuizen M.E., van den Berg A.P., Bouma G., et al.; Dutch Autoimmune Hepatitis Study Group. Calcineurin inhibitors in the treatment of adult autoimmune hepatitis: A systematic review. J Clin Transl Hepatol. 2022;10(6):1155–66. DOI: 10.14218/JCTH.2021.00535Baven-Pronk M.A., Hew J.M. Jr., Biewenga M., Tushuizen M.E., van den Berg A.P., Bouma G., et al.; Dutch Autoimmune Hepatitis Study Group. Calcineurin inhibitors in the treatment of adult autoimmune hepatitis: A systematic review. J Clin Transl Hepatol. 2022;10(6):1155–66. DOI: 10.14218/JCTH.2021.00535Еfe C., Taii H.A., Ytting H., Aehling N., Bhanji R.A., Hagstrom H., et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis. Dig Dis Sci. 2018;63(5):1348–54. DOI: 10.1007/s10620-018-5011-xЕfe C., Taii H.A., Ytting H., Aehling N., Bhanji R.A., Hagstrom H., et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis. Dig Dis Sci. 2018;63(5):1348–54. DOI: 10.1007/s10620-018-5011-xYtting H., Larsen F.S. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol. 2015;50(8):1025–31. DOI: 10.3109/00365521.2014.998271Ytting H., Larsen F.S. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol. 2015;50(8):1025–31. DOI: 10.3109/00365521.2014.998271Porcelli L., Quatrale A.E., Mantuano P., Silvestris N., Rolland J.F., Biancolillo L., et al. Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors. Curr Pharm Des. 2013;19(5):918–26.Porcelli L., Quatrale A.E., Mantuano P., Silvestris N., Rolland J.F., Biancolillo L., et al. Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors. Curr Pharm Des. 2013;19(5):918–26.Weinberg E.M. Current and emerging treatments for autoimmune hepatitis. Gastroenterol Hepatol (N Y). 2024;20(3):176–8.Weinberg E.M. Current and emerging treatments for autoimmune hepatitis. Gastroenterol Hepatol (N Y). 2024;20(3):176–8.Adao I., Klepper A., Tana M. AIH therapy: Beyond first-line. Curr Hepatology Rep. 2024;23:341–8. DOI: 10.1007/s11901-024-00657-4Adao I., Klepper A., Tana M. AIH therapy: Beyond first-line. Curr Hepatology Rep. 2024;23:341–8. DOI: 10.1007/s11901-024-00657-4Weiler-Normann C., Schramm C., Quaas A., Wiegard C., Glaubke C., Pannicke N., et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58(3):529–34. DOI: 10.1016/j.jhep.2012.11.010Weiler-Normann C., Schramm C., Quaas A., Wiegard C., Glaubke C., Pannicke N., et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58(3):529–34. DOI: 10.1016/j.jhep.2012.11.010Than N.N., Hodson J., Schmidt-Martin D., Taubert R., Wawman R.E., Botter M., et al. Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. JHEP Rep. 2019;1(6):437–45. DOI: 10.1016/j.jhepr.2019.10.005Than N.N., Hodson J., Schmidt-Martin D., Taubert R., Wawman R.E., Botter M., et al. Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. JHEP Rep. 2019;1(6):437–45. DOI: 10.1016/j.jhepr.2019.10.005Riveiro-Barciela M., Barreira-Díaz A., Esteban P., Rota R., Álvarez-Navascúes C., Pérez-Medrano I., et al. Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry. Liver Int. 2024;44(9):2303–14. DOI: 10.1111/liv.15970Riveiro-Barciela M., Barreira-Díaz A., Esteban P., Rota R., Álvarez-Navascúes C., Pérez-Medrano I., et al. Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry. Liver Int. 2024;44(9):2303–14. DOI: 10.1111/liv.15970Kolev M., Sarbu A.C., Möller B., Maurer B., Kollert F., Semmo N. Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis — a case series. J Transl Autoimmun. 2023;6:100189. DOI: 10.1016/j.jtauto.2023.100189Kolev M., Sarbu A.C., Möller B., Maurer B., Kollert F., Semmo N. Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis — a case series. J Transl Autoimmun. 2023;6:100189. DOI: 10.1016/j.jtauto.2023.100189Arvaniti P., Giannoulis G., Gabeta S., Zachou K., Koukoulis G.K., Dalekos G.N. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. JHEP Rep. 2020;2(4):100123. DOI: 10.1016/j.jhepr.2020.100123Arvaniti P., Giannoulis G., Gabeta S., Zachou K., Koukoulis G.K., Dalekos G.N. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. JHEP Rep. 2020;2(4):100123. DOI: 10.1016/j.jhepr.2020.100123Czaja A.J., Carpenter H.A. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 2003;23(2):116–23. DOI: 10.1034/j.1600-0676.2003.00810.xCzaja A.J., Carpenter H.A. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 2003;23(2):116–23. DOI: 10.1034/j.1600-0676.2003.00810.xÇavuşB., Akyuz F.,İliaz R., Atasoy A., Akyuz U., Demir K., et al. Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life? Int J Immunopathol Pharmacol. 2022;36:3946320221077860. DOI: 10.1177/03946320221077860ÇavuşB., Akyuz F.,İliaz R., Atasoy A., Akyuz U., Demir K., et al. Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life? Int J Immunopathol Pharmacol. 2022;36:3946320221077860. DOI: 10.1177/03946320221077860Hatoum S., Rockey D.C. Long-term outcomes of patients with autoimmune hepatitis induced cirrhosis after immunosuppressive treatment. Eur J Gastroenterol Hepatol. 2024;36(6):742–9. DOI: 10.1097/MEG.0000000000002714.Hatoum S., Rockey D.C. Long-term outcomes of patients with autoimmune hepatitis induced cirrhosis after immunosuppressive treatment. Eur J Gastroenterol Hepatol. 2024;36(6):742–9. DOI: 10.1097/MEG.0000000000002714.

The authors declare that there are no conflicts of interest present.